UBS Group’s Moringa Acquisition Corp Warrant MACAW Stock Holding History

UBS Group’s Portfolio MACAW Stock Details MACAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,528	Closed	-$105	–	10404
2024 Q2	$105	Buy	+1,528	New	+$119	﹤0.01%	9154
2023 Q4	–	Sell	-2,480	Closed	-$82	–	10163
2023 Q3	$82	Buy	+2,480	New	+$88	﹤0.01%	8931
2021 Q3	–	Sell	-196	Closed	–	–	10244
2021 Q2	$0	Buy	+196	New	+$124	﹤0.01%	9946

UBS Group's MACAW Position: Q3 2024 in Review

UBS Group sold out of Moringa Acquisition Corp Warrant (MACAW) in Q3 2024, closing a stake of 1,528 shares — an estimated $105 sold.

UBS Group first reported a position in MACAW in Q2 2021 and held it in 3 quarters. The position peaked at $105 in Q2 2024. 0 funds tracked by Wall St. Rank hold MACAW as of Q3 2024.

UBS Group reported no remaining Moringa Acquisition Corp Warrant position as of Q3 2024 after selling out during the quarter.
UBS Group sold 1,528 Moringa Acquisition Corp Warrant shares in Q3 2024, an estimated $105.
UBS Group first reported a position in Moringa Acquisition Corp Warrant in Q2 2021 and held it in 3 quarters.
UBS Group's Moringa Acquisition Corp Warrant position peaked at $105 in Q2 2024.
0 funds tracked by Wall St. Rank held Moringa Acquisition Corp Warrant as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.